151 related articles for article (PubMed ID: 10838662)
1. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.
Beecham EJ; Ortiz-Pujols S; Junghans RP
J Immunother; 2000; 23(3):332-43. PubMed ID: 10838662
[TBL] [Abstract][Full Text] [Related]
2. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
4. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death.
Beecham EJ; Ma Q; Ripley R; Junghans RP
J Immunother; 2000; 23(6):631-42. PubMed ID: 11186151
[TBL] [Abstract][Full Text] [Related]
5. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
6. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
7. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.
Yun CO; Nolan KF; Beecham EJ; Reisfeld RA; Junghans RP
Neoplasia; 2000; 2(5):449-59. PubMed ID: 11191112
[TBL] [Abstract][Full Text] [Related]
8. [T lymphocytes with chimeric receptor induce carcinoembryonic antigen-positive specific gastric carcinoma cells apoptosis].
Xu HY; Xu L; Gao JH; Li KZ; Dou KF
Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1053-7. PubMed ID: 17672971
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.
Patel SD; Ge Y; Moskalenko M; McArthur JG
J Immunother; 2000; 23(6):661-8. PubMed ID: 11186154
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
[TBL] [Abstract][Full Text] [Related]
12. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
[TBL] [Abstract][Full Text] [Related]
13. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
14. A loss of antitumor therapeutic activity of CEA DNA vaccines is associated with the lack of tumor cells' antigen presentation to Ag-specific CTLs in a colon cancer model.
Ahn E; Kim H; Han KT; Sin JI
Cancer Lett; 2015 Jan; 356(2 Pt B):676-85. PubMed ID: 25449428
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
16. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.
Cho HI; Kim HJ; Oh ST; Kim TG
Vaccine; 2003 Dec; 22(2):224-36. PubMed ID: 14615150
[TBL] [Abstract][Full Text] [Related]
17. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
[TBL] [Abstract][Full Text] [Related]
18. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
19. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044
[TBL] [Abstract][Full Text] [Related]
20. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.
Gyobu H; Tsuji T; Suzuki Y; Ohkuri T; Chamoto K; Kuroki M; Miyoshi H; Kawarada Y; Katoh H; Takeshima T; Nishimura T
Cancer Res; 2004 Feb; 64(4):1490-5. PubMed ID: 14973062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]